Fig. 5From: Integration of longitudinal deep-radiomics and clinical data improves the prediction of durable benefits to anti-PD-1/PD-L1 immunotherapy in advanced NSCLC patientsComparisons of ROC curves of longitudinal and ensemble RF models with clinical and radiomics data. a ROC curves for PFS6: PFS> 6 months. b ROC curve for PFS9: PFS > 9 monthsBack to article page